文献速递甲状腺疾病

免疫检查点抑制剂相关甲状腺炎的自然病程与转归

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
PubMed 文献 · Thyroid · 2018-01-01

该回顾性研究纳入657例接受ICI治疗的患者,其中43例(6.5%)发生免疫相关甲状腺炎,主要表现为无痛性甲状腺毒症,67%无症状,中位5.3周出现,84%随后进展为甲状腺功能减退,需长期左甲状腺素替代。联合ICI治疗时进展更迅速。

要点

  • ICI相关甲状腺炎多表现为早期无症状甲状腺毒症,随后快速进展为甲减。
  • 联合ICI治疗较单药治疗甲减发生更早(中位10周 vs 17周,P=0.029)。
  • ICI治疗期间应频繁监测甲状腺功能。

核心结论

  • ICI相关甲状腺炎表现为早期甲状腺毒症,多无症状,随后快速转为甲减,需长期左甲状腺素替代。

研究设计与样本

  • 回顾性研究,纳入2014年11月至2016年7月在MD Anderson癌症中心接受ICI治疗并因疑似甲状腺炎转诊内分泌科的癌症患者,最终43例符合纳入标准。

主要发现

  • 657例接受ICI治疗的患者中43例(6.5%)符合纳入标准,ICI包括伊匹木单抗+纳武利尤单抗(40%)、纳武利尤单抗(33%)、帕博利珠单抗(21%)和其他(7%)。
  • 从ICI开始至甲状腺毒症的中位时间为5.3周(范围0.6-19.6周),67%在甲状腺毒症阶段无症状,甲状腺毒症持续中位6周(范围2.6-39.7周)。
  • 37例(84%)发生甲减,中位时间为ICI开始后10.4周(范围3.4-48.7周),这些患者在甲减 onset 后中位随访57.4周(范围1-156.7周)期间持续使用左甲状腺素和ICI。
  • 4例未启动左甲状腺素即恢复,在中位随访11.35个月(范围4.43-14.43个月)时保持甲状腺功能正常。
  • 亚组分析显示伊匹木单抗+纳武利尤单抗 vs 纳武利尤单抗单药:至甲状腺毒症中位时间分别为2周(CI 3.5-8.4) vs 6周(CI 1.2-2.8),P=0.26;至甲减中位时间分别为10周(CI 8.1-11.9) vs 17周(CI 8.8-25.2),P=0.029。

临床怎么用

  • 对接受ICI治疗的患者应频繁监测甲状腺功能,以及时发现甲状腺毒症和甲减。
  • 发生ICI相关甲状腺炎时,多数患者需长期左甲状腺素替代治疗。
  • 联合ICI治疗患者应更密切监测,因甲状腺功能异常进展可能更迅速。

局限性

  • 回顾性研究,样本量较小(43例),可能存在选择偏倚。
  • 仅纳入转诊内分泌科的患者,可能低估总体发生率。
  • 随访时间有限,部分患者长期转归未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although immune-related thyroiditis (irT) with immune checkpoint inhibitors (ICI) is a common consequence, its natural course and management recommendations are not well characterized in existing guidelines. This study sought to investigate the evolution of irT and describe its course and sequelae. METHODS: This was a retrospective study of cancer patients treated with ICI between November 2014 and July 2016 at MD Anderson Cancer Center and referred for endocrinology evaluation for suspected irT. Patients included had normal baseline thyroid function tests prior to starting ICI and developed thyrotoxicosis due to irT. RESULTS: Of 657 patients treated with ICI during the study period, 43(6.5%) met the inclusion criteria. ICI included: ipilimumab + nivolumab (40%), nivolumab (33%), pembrolizumab (21%), and other (7%). Cancer diagnoses observed were melanoma (23%), renal-cell carcinoma (21%), lung cancer (19%), bladder cancer (12%), colon cancer (9%), and other cancers (15%). Median time from ICI start to thyrotoxicosis was 5.3 weeks (range 0.6-19.6 weeks). Clinically, patients presented with painless thyroiditis, and 67% were asymptomatic during the thyrotoxicosis phase. Thyrotoxicosis lasted a median of six weeks (range 2.6-39.7 weeks). Hypothyroidism developed in 37 (84%) patients at a median of 10.4 weeks (range 3.4-48.7 weeks) after starting ICI. These patients remained on levothyroxine and ICI at a median follow-up of 57.4 weeks (range 1-156.7 weeks) from hypothyroidism onset. Four patients recovered without initiating levothyroxine and remained euthyroid at a median follow-up of 11.35 months (range 4.43-14.43 months). Subgroup analysis of ipilimumab + nivolumab versus nivolumab alone showed a median time to thyrotoxicosis of two weeks [confidence interval (CI) 3.5-8.4] versus six weeks ([CI 1.2-2.8]; p = 0.26) and time to hypothyroidism of 10 weeks [CI 8.1-11.9] versus 17 weeks ([CI 8.8-25.2]; p = 0.029) after starting ICI. Thyroid peroxidase and thyroglobulin antibodies were present in 45% and 33% at the time of irT diagnosis. CONCLUSIONS: IrT manifests as an early onset of thyrotoxicosis, which is largely asymptomatic, followed by rapid transition to hypothyroidism requiring long-term levothyroxine substitution. The evolution of irT is more rapid with combination ICI. Frequent monitoring of thyroid function tests during ICI is warranted. Future guidelines need to recognize this entity and incorporate their management.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Iyer PC, Cabanillas ME, Waguespack SG, et al. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid. 2018. PMID: 30132401. doi:10.1089/thy.2018.0116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。